- In April 2024, Medeor Therapeutics completed its pivotal phase 3 clinical trial for MDR-101, a donor blood-derived cell therapy that is administered as a one-time treatment, intended to remove the daily requirement for immunosuppressant drugs in patients who receive kidney transplants
- In November 2022, Temple University, in collaboration with Veloxis Pharmaceuticals, initiated a Phase 4 clinical trial for Tacrolimus Extended-Release Oral Tablets, aiming to evaluate dosing strategies for de novo, once-daily extended-release tacrolimus (LCPT) in kidney transplant recipients
- In February 2022, Veloxis Pharmaceuticals Inc. announced that the U.S. FDA had granted fast-track designation to VEL-101, an investigational maintenance immunosuppressive agent developed by the company for preventing renal allograft rejection in kidney transplant recipients
- In November 2021, the U.S. FDA approved Takeda Pharma's, Livtencity (maribavir) for patients 12 years of age or older with post-transplant cytomegalovirus (CMV) infection
- In January 2020, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 (HR 5534) extended Medicare coverage for immunosuppressive drugs beyond the current 36-month limit, ensuring these medications are covered for the lifetime of kidney transplant recipients
